Stay updated on AK104 Plus Anlotinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AK104 Plus Anlotinib in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page revision was bumped from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.
    Difference
    0.8%
    Check dated 2025-09-13T17:16:41.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.8%
    Check dated 2025-09-06T14:46:29.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information.
    Difference
    10%
    Check dated 2025-08-30T11:33:43.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new completion status and a future date of August 19, 2025, while removing a previous status indicating that it was not actively recruiting and a date of March 3, 2025.
    Difference
    1%
    Check dated 2025-08-23T07:49:59.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-16T04:34:36.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-08T23:50:54.000Z thumbnail image

Stay in the know with updates to AK104 Plus Anlotinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.